|
市場調査レポート
商品コード
1335930
動物用APIの世界市場規模、シェア、産業動向分析レポート:投与経路別、APIタイプ別、合成タイプ別、動物タイプ別、地域別展望および予測、2023年~2030年Global Veterinary API Market Size, Share & Industry Trends Analysis Report By Route of Administration, By API Type, By Synthesis Type, By Animal Type, By Regional Outlook and Forecast, 2023 - 2030 |
||||||
|
動物用APIの世界市場規模、シェア、産業動向分析レポート:投与経路別、APIタイプ別、合成タイプ別、動物タイプ別、地域別展望および予測、2023年~2030年 |
出版日: 2023年07月31日
発行: KBV Research
ページ情報: 英文 294 Pages
納期: 即納可能
![]() |
動物用API市場規模は2030年までに129億米ドルに達し、予測期間中にCAGR6.4%の市場成長率で上昇すると予測されています。
しかし、タンパク質やペプチドのような動物用高分子原薬の合成には、特有の課題があります。このような困難は、高分子の複雑さと、その製造に必要な特殊な要件に起因します。高分子原薬の合成には時間とコストがかかります。合成手順の複雑さ、特殊な装置や試薬の必要性、低収量や精製困難の可能性など、すべてが費用の増加につながります。十分な量の高分子原薬を生産するためには、遺伝子工学、培養条件の改善、精製方法など、発現系を最適化する必要があります。
さらに、COVID-19の大流行によって動物飼育の必要性が減少したという議論は正確です。ほとんどの動物病院、診療所、その他の施設では、世界的大流行、感染症対策、州全体の封鎖措置のために、人の出入りが制限されていました。その結果、ほとんどの主要な関係者は、不十分なレベルで業務を行っていたか、より能力を高める必要があっています。動物用医薬品の生産能力だけでなく生産量の低下も、製品の入手不能やサプライチェーンの混乱につながる可能性があり、市場成長に悪影響を及ぼしました。
APIタイプの展望
APIタイプに基づき、市場は寄生虫駆除剤、ワクチン、抗菌剤、抗炎症剤、ホルモン剤、その他に分類されます。2022年には、寄生虫駆除剤市場が最も高い収益シェアを記録しました。動物用原薬生産への研究開発費の増加、コンパニオンアニマルおよび家畜動物の寄生虫感染の増加が、予測期間中の市場拡大に寄与すると予想されます。都市化の加速と可処分所得の増加により、これらの国々ではペットの所有率が上昇しています。これらの国々では、ペットの世話により多くの費用をかけようとする飼い主が増えており、これが同分野の需要を支えています。
投与経路の展望
投与経路によって、市場は経口剤、注射剤、外用剤、その他のセグメントに区分されます。注射剤は2022年に大きな市場収益シェアを占めると予想されています。このセグメントの拡大は、動物における慢性疾患の流行がワクチン需要を増大させていることに起因しています。さらに、家畜の個体数の増加や畜産業の増加、動物用製品の商業化がワクチン需要を増加させ、それによって同分野の拡大が促進されると予測されます。狂犬病、馬インフルエンザウイルス、口蹄疫に対する予防接種は、最も頻繁に実施されている動物用ワクチンであり、自然獲得免疫の再現により感染病原体の伝播を抑制します。
合成タイプの展望
市場は合成タイプ別に、化学ベースAPI、生物学的API、高活性APIに区分されます。2022年には、生物学的API分野が大きな市場収益シェアを獲得しました。これは、これらの製品が広く商業的に受け入れられていることと、生物学的動物用医薬品の研究が増加していることによる。多くの製薬会社や受託APIメーカーが、がんなどの慢性的な獣医学的疾患に対する特定の治療薬の開発のために生物学的APIを提供しています。
動物種の展望
動物の種類別に見ると、市場はコンパニオンアニマルと畜産動物に区分されます。2022年には、コンパニオンアニマルセグメンテーションが大きな収益シェアを獲得しました。これは、ペット飼育の増加、様々な疾患の有病率/発生率の増加、ペットヘルスケア費用の上昇、ペット用医薬品を提供する企業の多さによるものです。世界中のペットの飼い主は、抗生物質、抗感染症薬、非ステロイド性抗炎症薬(NSAIDs)、寄生虫駆除薬などの動物用医薬品にお金を払うことを望むようになっています。こうした要因は市場の成長に大きく寄与しています。
地域別展望
地域別では、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。北米は2022年に最も高い収益シェアを獲得し、市場を独占しました。大手動物ヘルスケア企業の地域的存在感の大きさ、有益な償還プログラム、人獣共通感染症の罹患率の上昇、獣医療における研究開発の拡大などが、この大幅なシェアに寄与しています。人畜共通感染症(人獣共通感染症)は、動物が感染症の発生源となることが多いことから、公衆衛生にさらなる危険をもたらすため、北米では重大な問題となっています。人畜共通感染症の高い蔓延率は、このセグメントの成長を導くさらなる要因です。
List of Figures
The Global Veterinary API Market size is expected to reach $12.9 billion by 2030, rising at a market growth of 6.4% CAGR during the forecast period.
The market expansion can be attributed to factors such as the increasing demand for meat and meat products, the growing concern for animal health and welfare, and technological advancements in animal husbandry. Therefore, the Hormones segment generated $566.6 million revenue in the market in 2022. Animal hormones are substances produced by an animal's body that regulate numerous vital physiological processes, including growth, development, reproduction, and metabolism. Increased understanding among farm and pet owners regarding the accessibility of veterinarians and animal healthcare products is the primary reason for the significant increase in animal medicalization rates in developing nations. The increased number of veterinary visits increased the demand for diagnostic tests and treatment options, increasing the demand for anti-infectives, anti-microbial, antiparasitics, vaccines, etc. Some of the factors impacting the market are increase in understanding of animal health and welfare, increasing prevalence of transboundary and zoonotic diseases, and difficulties in large-molecular-weight API synthesis.
The public's cognizance of animal health and welfare has increased significantly. People are becoming increasingly aware of the significance of providing appropriate care and consideration to animals, including domesticated companions, livestock, and untamed animals. Many organizations are examining the factors that have contributed to the growing awareness of animal health and welfare and the consequences for the veterinary industry and society. Local and international animal welfare organizations have been essential in raising understanding about animal health and welfare. These organizations campaign for the rights and well-being of animals, encourage responsible ownership of pets, and emphasize the significance of humane animal treatment. Due to their potential to cause significant injury to both animals and humans, transboundary and zoonotic diseases are currently a developing concern worldwide. These diseases, like avian influenza, rabies, and African swine fever, threaten public health, animal welfare, and international trade. Consequently, the use of veterinary active pharmaceutical ingredients (APIs) to fight against the spread of these diseases has increased. The availability of adequate and high-quality veterinary active pharmaceutical ingredients is crucial for supporting these initiatives, enabling international cooperation, and mitigating the detrimental effects of such ailments on public health and international trade.
However, the synthesis of large molecule APIs, like proteins and peptides, for veterinary applications presents unique challenges. These difficulties stem from the complexity of large molecules and the particular requirements for their production. Synthesis of large molecule APIs can be time-consuming and expensive. The complexity of the synthesis procedure, the need for specialized apparatus and reagents, and the possibility of low yields or purification difficulties can all contribute to increased expenses. It is necessary to optimize expression systems, such as genetic engineering, improvement of culture conditions, and purification methods, to produce enough large molecule APIs.
Furthermore, the argument that the COVID-19 pandemic decreased the need for animal care is accurate. In most veterinary hospitals, clinics, and other facilities, foot traffic was restricted due to the global outbreak, infection control measures, and state-wide lockdowns. Consequently, most key actors operated at a deficient level or need to be more competent. Lower output, as well as capacity in veterinary pharmaceutical production, might result in product unavailability and disrupted supply chains, which had a negative impact on market growth.
API Type Outlook
Based on API type, the market is categorized into parasiticides, vaccines, antimicrobials, anti-inflammatories, hormones, and others. In 2022, the parasiticides segment of the market recorded the highest revenue share. Increasing R&D spending on veterinary API production and rising parasitic infections in companion and livestock animals are expected to contribute to market expansion over the forecast period. Due to accelerated urbanization and increasing disposable income, pet ownership is rising in these nations. In these countries, more pet owners are willing to spend more on their pets' care, which supports the segment's demand.
Route of Administration Outlook
Based on route of administration, the market is segmented into oral, injectable, topical, and other segments. Injectables are anticipated to have a significant market revenue share in 2022. The segment's expansion can be attributed to the prevalence of chronic diseases in animals, which has increased the demand for vaccines. In addition, increasing livestock populations and animal husbandry and commercializing animal products are projected to increase demand for vaccines, thereby driving segment expansion. Vaccinations against rabies, equine influenza virus, and foot-and-mouth disease are the most frequently administered animal vaccines, which inhibit the transmission of infectious pathogens by reproducing naturally acquired immunity.
Synthesis Type Outlook
Based on synthesis type, the market is segmented by type of synthesis into chemical-based API, biological API, and highly potent API. In 2022, the biological API segment captured a significant market revenue share. This results from the widespread commercial acceptance of these products and increased research on biological veterinary medications. A number of pharmaceutical companies and contract API manufacturers provide biological APIs for the development of specific therapeutic medications for chronic veterinary diseases such as cancer.
Animal Type Outlook
On the basis of animal type, the market is segmented by animal type into companion animals and livestock animals. In 2022, the companion animals segment of the market attained a substantial revenue share. This is due to the rise in pet ownership, the increasing prevalence/incidence of various diseases, the rising cost of pet healthcare, and the large number of companies offering pet pharmaceutical products. Pet owners around the globe are increasingly willing to pay for veterinary medications, such as antibiotics, anti-infectives, nonsteroidal anti-inflammatory drugs (NSAIDs), and parasiticides, among others. Such factors greatly contribute to market growth.
Regional Outlook
Regionally, the market is analyzed in North America, Europe, Asia Pacific, and LAMEA. North America dominated the market in 2022 by generating the highest revenue share. Significant localized prominence of major animal healthcare companies, beneficial reimbursement programs, an elevated incidence of zoonotic diseases, and expanding R&D in veterinary healthcare all contribute to this substantial share. Zoonoses (zoonotic diseases) are a significant problem in North America because they pose an additional hazard to public health, given that animals are frequently the source of infectious diseases. The high prevalence of zoonotic diseases is a further factor leading to segment growth.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Zoetis, Inc., Elanco Animal Health, Inc., Merck & Co., Inc., Virbac, Vetoquinol SA (Soparfin SCA), Sequent Scientific Limited, Phibro Animal Health Corporation, Febbrica Italina Sintetici S.P.A. (Nine Trees Group S.p.A) and Excel Industries Limited.
Strategies Deployed in Veterinary API Market
Sep-2022: Boehringer Ingelheim Animal Health introduced Fencovis, a new calf sour vaccine with a prevention claim, offering unresistant immunity to calves through the cows' maternal colostrum. With Fencovis, a prevention claims against E. coli F5 and bovine rotavirus, Boehringer Ingelheim Animal Health offers a holistic lean approach to cattle farming through its support and training services.
Sep-2022: Zoetis, Inc. took over Jurox, a provider of livestock and Companion Animal products. Through this acquisition, Jurox brings Zoetis a spectrum of key products primed for larger global expansion, a valuable animal health suite, consisting of Alfaxan, an anesthetic product for companion animals.
Aug-2022: Merck & Co., Inc. announced expanded production of its facility based in Carlow. The expansion would play a key role in making sure that they continue to sustain future supply to meet medical requirements.
Jul-2022: Virbac launched TENOTRYL (enrofloxacin), an injectable solution for use in swine and cattle. This launch aims to serve veterinarians and customers, swine, and cattle producers, and also a suite of new alternatives to improve the health of livestock and finally their profitability.
Jul-2022: Zoetis completed the acquisition of Fish Vet Group from Benchmark Holdings PLC, a leading bioagtech company. Following this acquisition, Fish Vet Group would be a strategic addition to Zoetis' Pharmaq business which develops and sells fish vaccines and provides services in diagnostics and vaccination for aquaculture.
Jan-2022: Zoetis Inc. got FDA approval for Solensia, a once-monthly injection administered in the veterinary clinic. The approved injection aims to control the pain of osteoarthritis (OA) in cats, helping enhance their comfort, mobility, and overall well-being.
May-2021: Boehringer Ingelheim India unveiled poultry vaccine VAXXITEK HVT+IBD, an advanced recombinant vaccine. The launched vaccine is a single-shot vaccine, making sure life-long protection for all kinds of production chickens, namely broiler, layer, and breeder.
May-2021: Zoetis released the porcine circovirus vaccine, the only vaccine that consists of two porcine circovirus type two genotypes. The vaccine offers wider coverage against PCV2 and protection against two of the main pathogens in the worldwide pig industry.
Jan-2021: Boehringer Ingelheim partnered with PetMedix, a company engaged in creating treatment solutions for pets. Following this partnership, both companies would aim to advance novel and changeable companion animal antibody therapeutics utilizing PetMedix's properietary Ky9™ platform. Additionally, PetMedix would undertake discovery activities against a number of key targets, and Boehringer Ingelheim would work to develop and bring these therapies to market.
Aug-2019: Elanco Animal Health Inc. took over Prevtec Microbia Inc., a biotechnology startup with expertise in the development of vaccines that help prevent bacteria diseases in food animals. Prevtec offers the line of Coliprotec vaccine, a product designed to protect pigs. Following this acquisition, Elanco would be an exclusive distributor for Coliprotec across Europe and Canada. Moreover, this acquisition brings Prevtec's research and development programs to Elanco's portfolio.
Jun-2019: Elanco Animal Health completed the acquisition of Aratana Therapeutics, a pet therapeutics company engaged in the development and sales of advanced therapeutics for dogs and cats, and developer of Galliprnat, a first-of-its-kind canine NSAID for osteoarthritis. This acquisition enables Elanco to capture the complete value of the growing product Galliprant and introduce two new products - Entyce, the only FDA-approved veterinary therapeutic, and Nocita, a long-acting local anaesthetic, in Elanco's portfolio.
Market Segments covered in the Report:
By Route of Administration
By API Type
By Synthesis Type
By Animal Type
By Geography
Companies Profiled
Unique Offerings from KBV Research